Epkinly a novel drug approved by fda 

Share This Post

Epkinly is a novel drug approved by fda (on last May 19) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. The IgG1 antibody Epcoritamab is manufactured in CHOcells. 

👉 CHO cells play a fundamental role in the manufacturing of many biological products and are widely used also in research and development. 

Magellan Biologics’ CHO4Tx® is a whole system (CHO 4Tx® cell line + CHO 4Tx® media + CHO 4Tx® protocol) dedicated to Transient Protein Expression in CHO cells. By making this process easy, efficient and cost effective in particular for high-throughput screening Magellan Biologics & Consulting supports research and development projects whole around the world. 

Get updates

Subscribe To Our Newsletter

More To Explore

Interested in our products?

Drop us a line and keep in touch

Your cart is currently empty.

Welcome on board!

Subrscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content